title: Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
abstract: The aim of the study was to compare clinical variables between MCI patients at different risk for Alzheimer's disease (AD) according to their biomarker profile. Fifty-four percent out of 39 MCI patients had a low Abeta42 and high tau in cerebrospinal fluid (CSF) (high-risk), 26% either a low CSF Abeta32 or high CSF tau (intermediate-risk) and 20% a normal CSF Abeta42 and tau (low-risk). Both high-and intermediate-risk subjects differed from the low-risk group in episodic memory, executive functions and the preclinical AD scale (PAS),which combines a set of clinical parameters. Subjects at high risk did not differ from subjects with an intermediate risk. Abeta42 levels correlated with the MTA and PAS scores, tau levels with episodic memory. These correlations suggest that the biomarkers are not independent when compared to the other AD markers. Longitudinal studies are necessary to interpret the correlations between biomarkers, imaging, and neuropsychological markers.
authors.affiliation: Department of Neurology Alzheimer Centre, VU University Medical Centre, Amsterdam, the Netherlands. niki.schoonenboom@vumc.nl
authors.forename: S N M
authors.initials: SN
authors.lastname: Schoonenboom
authors.forename: P J
authors.initials: PJ
authors.lastname: Visser
authors.forename: C
authors.initials: C
authors.lastname: Mulder
authors.forename: J
authors.initials: J
authors.lastname: Lindeboom
authors.forename: E J
authors.initials: EJ
authors.lastname: Van Elk
authors.forename: G J
authors.initials: GJ
authors.lastname: Van Kamp
authors.forename: P H
authors.initials: PH
authors.lastname: Scheltens
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000150:complications / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000209:etiology / Q000473:pathology; D005260:Female; D005838:Genotype; D006801:Humans; D016014:Linear Models; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008568:Memory / Q000502:physiology; D008609:Mental Status Schedule / Q000706:statistics & numerical data; D008875:Middle Aged; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011340:Problem Solving / Q000502:physiology; D012189:Retrospective Studies; D012306:Risk; D018709:Statistics, Nonparametric; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins